Abaza Yasmin M, Alemany Carlos
Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA.
Cancer Institute of Florida, Florida Hospital, 2501 North Orange Avenue, Suite 689, Orlando, FL 32804, USA.
Case Rep Urol. 2014;2014:489686. doi: 10.1155/2014/489686. Epub 2014 Aug 18.
Primary urethral cancer is rare and accounts for only 0.003% of all malignancies arising from the female genitourinary tract. Due to the rarity of this disease, no consensus exists regarding the optimal therapeutic approach. Nanoparticle albumin-bound-paclitaxel has been shown to be effective in the treatment of a number of malignancies including metastatic breast, pancreatic, and bladder cancer. We present a 67-year-old woman with advanced metastatic urethral adenocarcinoma resistant to two lines of chemotherapy (ifosfamide/paclitaxel/cisplatin and irinotecan/5-fluorouracil/leucovorin) that showed a dramatic response to nanoparticle albumin-bound-paclitaxel. This is the first case report to document the use and efficacy of nanoparticle albumin-bound-paclitaxel in the treatment of unresectable metastatic urethral cancer.
原发性尿道癌很罕见，仅占女性泌尿生殖道所有恶性肿瘤的0.003%。由于这种疾病罕见，关于最佳治疗方法尚无共识。纳米白蛋白结合型紫杉醇已被证明对包括转移性乳腺癌、胰腺癌和膀胱癌在内的多种恶性肿瘤有效。我们报告了一名67岁患有晚期转移性尿道腺癌的女性，她对两线化疗（异环磷酰胺/紫杉醇/顺铂和伊立替康/5-氟尿嘧啶/亚叶酸钙）耐药，但对纳米白蛋白结合型紫杉醇表现出显著反应。这是第一例记录纳米白蛋白结合型紫杉醇在治疗不可切除转移性尿道癌中的应用及疗效的病例报告。
